Recombinant Human Coagulation Factor VIII (sinocelltech)

重组人凝血因子VIII（神州细胞）

Report date: 2026/03/04 20:01:44

Base Information

Drug NameRecombinant Human Coagulation Factor VIII (sinocelltech)
Drug Alias Name重组八因子omfiloctocog alfa欧洛凝血素Ⅷ-αSCT-800
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factorBiologics > Biosimilar
Mechanisms of ActionCoagulation factor X stimulantsBlood coagulation pathway activationCoagulation factor VIII replacements
TargetsCoagulation factor X
Therapy Area/IndicationsBlood Loss, SurgicalHemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaHemophilia A
Original Approved Country/TerritoryMainland China
Original Approved Date2021/07/20
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinoCelltech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsBlood Loss, SurgicalHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BD02
Related LinksN/A